- Despite recent investor skepticism, the Phase 3 COVID-19 results for Veru Inc's VERU sabizabulin published in the New England Journal of Medicine "addressed most concerns," Jefferies writes.
- The analyst sees the data as "further derisking" Veru's COVID opportunity and reiterates a Buy rating on the shares with a $55 price target.
- The data likely signals an FDA Emergency Use Authorization in 30 days, Howerton contends.
- Related: Veru Seeks FDA Emergency Use Nod For Its COVID-19 Treatment.
- Patients enrolled are, in fact, sicker and support the higher mortality observed.
- There was no meaningful impact of region on outcomes. The baseline demographics were well-balanced across arms, says the analyst.
- Sabizabulin treatment showed a statistically significant and clinically meaningful 55.2% reduction in deaths compared to placebo in moderate-severe hospitalized COVID-19 patients.
- The sabizabulin treatment had a significant and clinically meaningful reduction in days in ICU, mechanical ventilation, and the hospital.
- Sabizabulin was well tolerated with a more favorable safety profile compared to placebo.
- HC Wainwright notes that no current FDA-approved or authorized COVID-19 therapeutics in the hospital setting can achieve over 50% relative reduction in deaths.
- Hence, sabizabulin can potentially become the new standard of care for hospitalized moderate-severe COVID-19 patients if its EUA application is granted.
- Price Action: VERU shares are up 4.53% at $13.61 during the market session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
